The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by HC Wainwright & Co. on October 24, 2024. The analyst firm set a price target for $0.00 expecting AVTX to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Avalo Therapeutics (NASDAQ:AVTX) was provided by HC Wainwright & Co., and Avalo Therapeutics initiated their neutral rating.

The last upgrade for Avalo Therapeutics Inc happened on April 16, 2024 when Oppenheimer raised their price target to $35. Oppenheimer previously had a perform for Avalo Therapeutics Inc.

The last downgrade for Avalo Therapeutics Inc happened on June 27, 2023 when Oppenheimer changed their price target from N/A to N/A for Avalo Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on October 24, 2024 so you should expect the next rating to be made available sometime around October 24, 2025.

While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a initiated with a price target of $0.00 to $0.00. The current price Avalo Therapeutics (AVTX) is trading at is $10.30, which is out of the analyst’s predicted range.